FogPharma’s Post

Our CEO Iraj Ali shared his perspective on the complexities of launching an IPO in an unpredictable market in the second instalment of Citeline Commercial’s #ScripAsks annual series, which highlights industry leaders, experts and investors’ expectations for the year ahead.   Read the full article here: https://lnkd.in/eCKp9ZMA #Oncology #Neoantigens #Clonals

ICYMI: LucidQuest Views >>> How our benchmarking analysis contributed to a Hemato-Oncology company’s sales and pricing strategy for specific agents. #Casestudies #Oncology Comment below! >>> lqventures.com

Step Pharma was founded in 2014 based on the science of Professor Alain Fischer at the Imagine Institute in Paris. By characterising CTPS1 mutations in children, Professor Fischer and his team laid the foundations for understanding the role of CTPS1 in both malignant and normal cell proliferation.    Find out more about how Step Pharma was created from this groundbreaking discovery by Professor Alain Fischer.    #CTPS1 #oncology #drugdiscovery 

On this National Science Day, we celebrate the marvel of science all around us. #caplinonelabs #caplinpointlaboratories #caplinpoint #caplinsteriles #caplinone #sterilemanufacturing #pharmamanufacturing #injectables #formulations #RandD #nationalscienceday #science #solidorals #cancertreatment #oncology #affordablehealthcareforall

Less than a week to go until the #BiotechShowcase! We are looking forward to discussing our innovative #LiquidBiopsy platform with you all on the 9th Jan. #jpm2024 #venturecapital #privateequity #oncology #Dxcover J.P. Morgan

Heading to #ASCO? Come meet me at booth 13059 to learn about how Tempus MultiOmics accelerates drug discovery. #personalizedmedicine #oncology #multiomics

Ever curious about the future of #syntheticlethality and the discovery of novel synthetic lethal targets in #oncology? So are we, and we have some answers! Ryvu Therapeutics is at the forefront with our advanced drug discovery platform, utilizing human primary models and patient-derived samples. This innovative method is revolutionizing identification of synthetic lethal targets within oncogenic pathways. At #AACR24 today, we're excited to share validating data from our approach using a model CRC system to identify KRAS-specific synthetic lethal targets employing patient-derived cells. #syntheticlethality #newtargets #KRAS

Stop by the Caris Booth (#13081) and recharge with a Caramel Logo Latte. While you're waiting, be prepared to be amazed by our industry-leading molecular profiling and data solutions that will supercharge your oncology program development. #asco2023 #CarisLifeSciences #nextgenerationsequencing #oncology #machinelearning #drugdevelopment

We are regularly approached by pharmaceutical groups to provide very rich, in-depth and, above all, multi-omics real-world data. We have developed a battery of tools to capture and enrich data, as well as to de-identify and consolidate it. We have central platforms that enable industrialists and academics to test their algorithms, to easily implement batteries of filters and the very best in image processing algorithms, all to serve our customers: we take care of enriching existing cohorts, and valorizing them in strict compliance with regulatory constraints. Our CIAN cohorts are the result of this collaboration with our partner sites, and enable us to rapidly provide our customers with qualified data for building synthetic control arms, for example.  #ClinicalResearch #ImagingAnalytics #GameChanger #CIANProject #CancerResearch #PatientsCohort #RWD #Controlarms

If you are interested to learn more about the role of biomarkers in oncology drug development and personalized medicine, or how biomarker assays may evolve over the next 5-10 years, then this panel discussion with NAVEEN DAKAPPAGARI from Navigate BioPharma Services, Inc. and Jialu Liu from Frontage Laboratories, Inc might be for you. #precisionmedicine #oncology